Detail akcie Xencor online

Business Summary: Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Xencor Inc revenues increased 14% to $125.6M. Net loss decreased 60% to $91.9M. Revenues reflect Royalties segment increase from $600K to $80.3M, Milestone segment increase of 31% to $45.3M. Lower net loss reflects Unrealized gain (loss) recorded on equit increase from $32.7M (expense) to $87.1M (income), Net gain recorded on sale of equity secu increase from $1.3M to $14.4M (income).